New combo therapy aims to speed healing for fragile skin disease
NCT ID NCT06834035
Summary
This study is testing whether adding IV IgG (intravenous immunoglobulin) to an existing gene therapy (VYJUVEK) helps wounds heal faster and better in people with recessive dystrophic epidermolysis bullosa (RDEB). It will enroll 8 participants who already have significant blistering and are currently using VYJUVEK. Researchers will measure changes in wound size and track safety to see if the combination improves quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGRedwood City, California, 94163, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.